These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 33954824)

  • 21. Barriers and facilitators to pre-exposure prophylaxis uptake among male sex workers in Mexico: an application of the RE-AIM framework.
    Kadiamada-Ibarra H; Hawley NL; Sosa-Rubí SG; Wilson-Barthes M; Franco RR; Galárraga O
    BMC Public Health; 2021 Nov; 21(1):2174. PubMed ID: 34837988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub-Saharan Africa: a mixed methods analysis.
    Roberts ST; Mancuso N; Williams K; Nabunya HK; Mposula H; Mugocha C; Mvinjelwa P; Garcia M; Szydlo DW; Soto-Torres L; Ngure K; Hosek S
    J Int AIDS Soc; 2023 Nov; 26(11):e26189. PubMed ID: 37936551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk perception, safer sex practices and PrEP enthusiasm: barriers and facilitators to oral HIV pre-exposure prophylaxis in Black African and Black Caribbean women in the UK.
    Nakasone SE; Young I; Estcourt CS; Calliste J; Flowers P; Ridgway J; Shahmanesh M
    Sex Transm Infect; 2020 Aug; 96(5):349-354. PubMed ID: 32532928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "These Girls Have a Chance to be the Future Generation of HIV Negative": Experiences of Implementing a PrEP Programme for Adolescent Girls and Young Women in South Africa.
    Duby Z; Bunce B; Fowler C; Jonas K; Bergh K; Govindasamy D; Wagner C; Mathews C
    AIDS Behav; 2023 Jan; 27(1):134-149. PubMed ID: 35793053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.
    Velloza J; Khoza N; Scorgie F; Chitukuta M; Mutero P; Mutiti K; Mangxilana N; Nobula L; Bulterys MA; Atujuna M; Hosek S; Heffron R; Bekker LG; Mgodi N; Chirenje M; Celum C; Delany-Moretlwe S;
    J Int AIDS Soc; 2020 Mar; 23(3):e25463. PubMed ID: 32144874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Community perspectives on barriers and challenges to HIV pre-exposure prophylaxis access by men who have sex with men and female sex workers access in Nigeria.
    Emmanuel G; Folayan M; Undelikwe G; Ochonye B; Jayeoba T; Yusuf A; Aiwonodagbon B; Bilali C; Umoh P; Ojemeiri K; Kalaiwo A
    BMC Public Health; 2020 Jan; 20(1):69. PubMed ID: 31941469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Test but not treat: Community members' experiences with barriers and facilitators to universal antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa.
    Iwuji C; Chimukuche RS; Zuma T; Plazy M; Larmarange J; Orne-Gliemann J; Siedner M; Shahmanesh M; Seeley J
    PLoS One; 2020; 15(9):e0239513. PubMed ID: 32970730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The potential effect of pre-exposure prophylaxis (PrEP) roll-out on sexual-risk behaviour among adolescents and young people in East and southern Africa.
    Ssemata AS; Muhumuza R; Stranix-Chibanda L; Nematadzira T; Ahmed N; Hornschuh S; Dietrich JJ; Tshabalala G; Atujuna M; Ndekezi D; Nalubega P; Awino E; Weiss HA; Fox J; Seeley J
    Afr J AIDS Res; 2022 Mar; 21(1):1-7. PubMed ID: 35361057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Policy considerations for scaling up access to HIV pre-exposure prophylaxis for adolescent girls and young women: Examples from Kenya, South Africa, and Uganda.
    Lane J; Brezak A; Patel P; Verani AR; Benech I; Katz A
    Int J Health Plann Manage; 2021 Sep; 36(5):1789-1808. PubMed ID: 34159630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PrEP awareness and engagement among transgender women in South Africa: a cross-sectional, mixed methods study.
    Poteat T; Malik M; van der Merwe LLA; Cloete A; Adams D; Nonyane BAS; Wirtz AL
    Lancet HIV; 2020 Dec; 7(12):e825-e834. PubMed ID: 32622370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sociocultural and structural influences on HIV Pre-Exposure Prophylaxis (PrEP) Engagement and Uptake among African American Young adults.
    Ayangeakaa SD; Kerr J; Combs RM; Harris LM; Sears JS; Parker K; Sterrett-Hong E
    BMC Public Health; 2023 Jul; 23(1):1427. PubMed ID: 37495954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Community perspectives on addressing and responding to HIV-testing, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) among African, Caribbean and Black (ACB) people in Ontario, Canada.
    Etowa J; Tharao W; Mbuagbaw L; Baidoobonso S; Hyman I; Obiorah S; Aden M; Etowa EB; Gebremeskel A; Kihembo M; Nelson L; Husbands W
    BMC Public Health; 2022 May; 22(1):913. PubMed ID: 35525946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acceptability of HIV Pre-Exposure Prophylaxis (PrEP) and Implementation Challenges Among Men Who Have Sex with Men in India: A Qualitative Investigation.
    Chakrapani V; Newman PA; Shunmugam M; Mengle S; Varghese J; Nelson R; Bharat S
    AIDS Patient Care STDS; 2015 Oct; 29(10):569-77. PubMed ID: 26348459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Community Health Care Providers' Perspectives on Human Immunodeficiency Virus Pre-Exposure Prophylaxis Use Among Black Women in Eastern Virginia.
    Pitchford K; Shangani S; Dawson C; Masa R; Heron K
    AIDS Patient Care STDS; 2024 Mar; 38(3):123-133. PubMed ID: 38471092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the acceptability of, adherence to and preference for a dual prevention pill (DPP) for HIV and pregnancy prevention compared to oral pre-exposure prophylaxis (PrEP) and oral contraception taken separately: protocols for two randomised, controlled, cross-over studies in South Africa and Zimbabwe.
    Friedland BA; Mgodi NM; Palanee-Phillips T; Mathur S; Plagianos MG; Bruce IV; Lansiaux M; Murombedzi C; Musara P; Dandadzi A; Reddy K; Ndlovu N; Zulu SK; Shale LR; Zieman B; Haddad LB
    BMJ Open; 2024 Mar; 14(3):e075381. PubMed ID: 38479746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Key stakeholders' perspectives on providing oral pre-exposure prophylaxis as HIV-prevention standard of care in clinical trials in South Africa.
    Beesham I; Milford C; Joseph Davey DL; Smit J; Mansoor LE; Beksinska M
    Afr J AIDS Res; 2023 Apr; 22(1):18-26. PubMed ID: 36951406
    [No Abstract]   [Full Text] [Related]  

  • 37. HIV Pre-Exposure Prophylaxis Uptake Among High-Risk Population in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.
    Nagai H; Ankomah A; Fuseini K; Adiibokah E; Semahegn A; Tagoe H
    AIDS Patient Care STDS; 2024 Feb; 38(2):70-81. PubMed ID: 38381951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with willingness to use oral pre-exposure prophylaxis (PrEP) in a fisher-folk community in peri-urban Kampala, Uganda.
    Ssuna B; Katahoire A; Armstrong-Hough M; Kalibbala D; Kalyango JN; Kiweewa FM
    BMC Public Health; 2022 Mar; 22(1):468. PubMed ID: 35264123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.
    Amico KR; Wallace M; Bekker LG; Roux S; Atujuna M; Sebastian E; Dye BJ; Elharrar V; Grant RM
    AIDS Behav; 2017 May; 21(5):1361-1375. PubMed ID: 27317411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study.
    Eisingerich AB; Wheelock A; Gomez GB; Garnett GP; Dybul MR; Piot PK
    PLoS One; 2012; 7(1):e28238. PubMed ID: 22247757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.